Know Cancer

or
forgot password

Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas


N/A
N/A
N/A
Open (Enrolling)
Female
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Thank you

Trial Information

Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas


OBJECTIVES:

- Evaluate the ability of the microculture kinetic (MiCK) assay to predict the outcome of
patients with ovarian, fallopian tube, or primary peritoneal adenocarcinoma treated
with first-line chemotherapy.

- Evaluate the ability of the MiCK assay to guide chemotherapy in a third-line,
refractory treatment setting (exclusive of anti-vascular endothelial growth factor) in
these patients.

OUTLINE: Patients are stratified according to prior chemotherapy (no [stratum I] vs yes
[stratum II]).

Tumor tissue and/or effusion specimens are collected at baseline. Specimens are examined by
the microculture kinetic (MiCK) assay and immunocytochemical or flow cytometry assay.

MiCK assay results do not influence treatment for stratum I patients. Stratum II patients
may receive treatment based on MiCK assay results for tumor sensitivity to specific
chemotherapy drugs.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Pathologically confirmed adenocarcinoma of 1 of the following types:

- Ovarian

- Primary peritoneal

- Fallopian tube

- Must meet 1 of the following criteria:

- De novo malignancy with no prior chemotherapy

- Advanced refractory malignancy with ≤ 2 standard chemotherapy treatment
protocols

- Tumor must be accessible for biopsy or drainage of effusions

- Chemotherapy is considered a treatment option

- No symptomatic or uncontrolled parenchymal brain metastases

- No meningeal metastasis

PATIENT CHARACTERISTICS:

- Not pregnant

- Negative pregnancy test

- Fertile patients must agree to use effective contraception

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Correlation of a statistically significant discriminator of sensitivity with complete response rate

Safety Issue:

No

Principal Investigator

Vladimir D. Kravtsov, MD

Investigator Role:

Study Chair

Investigator Affiliation:

DiaTech Oncology

Authority:

Unspecified

Study ID:

CDR0000491440

NCT ID:

NCT00897039

Start Date:

March 2006

Completion Date:

Related Keywords:

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer
  • ovarian serous cystadenocarcinoma
  • ovarian undifferentiated adenocarcinoma
  • recurrent ovarian epithelial cancer
  • ovarian clear cell cystadenocarcinoma
  • ovarian endometrioid adenocarcinoma
  • ovarian mucinous cystadenocarcinoma
  • stage IA ovarian epithelial cancer
  • stage IB ovarian epithelial cancer
  • stage IC ovarian epithelial cancer
  • stage IIA ovarian epithelial cancer
  • stage IIB ovarian epithelial cancer
  • stage IIC ovarian epithelial cancer
  • stage IIIA ovarian epithelial cancer
  • stage IIIB ovarian epithelial cancer
  • stage IIIC ovarian epithelial cancer
  • recurrent primary peritoneal cavity cancer
  • stage IA primary peritoneal cavity cancer
  • stage IB primary peritoneal cavity cancer
  • stage IC primary peritoneal cavity cancer
  • stage IIA primary peritoneal cavity cancer
  • stage IIB primary peritoneal cavity cancer
  • stage IIC primary peritoneal cavity cancer
  • stage IIIA primary peritoneal cavity cancer
  • stage IIIB primary peritoneal cavity cancer
  • stage IIIC primary peritoneal cavity cancer
  • recurrent fallopian tube cancer
  • stage IA fallopian tube cancer
  • stage IB fallopian tube cancer
  • stage IC fallopian tube cancer
  • stage IIA fallopian tube cancer
  • stage IIB fallopian tube cancer
  • stage IIC fallopian tube cancer
  • stage IIIA fallopian tube cancer
  • stage IIIB fallopian tube cancer
  • stage IIIC fallopian tube cancer
  • Adenocarcinoma
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms

Name

Location
Southeastern Gynecologic Oncology, LLP - Northside Atlanta, Georgia  30342